All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
#ASH24: Hodgkin lymphoma
Bookmark this article
To update you on the exciting content presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, Dec 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up with our live social media relating to Hodgkin lymphoma, here.
CONGRESS | #ASH24 | POSTER
— Lymphoma Hub (@lymphomahub) December 12, 2024
Bruce D. Cheson, Center for Cancer and Blood Disorders, shared long term data from a phase II trial of brentuximab vedotin and nivolumab in older (>60 yrs) patients with untreated Hodgkin #lymphoma.
At a median follow-up of 58.5 months, 58.7% of the… pic.twitter.com/Q3NtQOlvgV
CONGRESS | #ASH24 | Alison Moskowitz @MSKCancerCenter discusses the feasibility of pembrolizumab maintenance after pembro-GVD for R/R HL in CR. Overall 24-mo PFS 60%, stage I-III 24-mo PFS 72%, stage IV 24-mo PFS 37%. Pts with stage IV are more likely to require transplant.… pic.twitter.com/T6yWi2VyyQ
— Lymphoma Hub (@lymphomahub) December 9, 2024
CONGRESS | #ASH24 | Justin Ferdinandus @jusferdinandus @UKKoeln shares results from the phase II portion of the GHSG HD21 trial of PET-guided BrECADD in older patients with advanced-stage cHL. At a median FU of 23 mo, 12 mo PFS 95.1%, 24 mo PFS 91.5, 12 mo OS 96.2%, 24 mo OS… pic.twitter.com/u3sN9YgHzg
— Lymphoma Hub (@lymphomahub) December 9, 2024
CONGRESS | #ASH24 | PRESENTATION@LisaRoth_MD @WeillCornell shares updated results from the phase II KEYNOTE-667 trial.
— Lymphoma Hub (@lymphomahub) December 9, 2024
After additional follow-up, pembrolizumab plus AVD consolidation, radiotherapy, and pembrolizumab maintenance demonstrated promising activity and a manageable… pic.twitter.com/lX0MUjRERb
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
2 votes - 21 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox